Division of Cancer Epidemiology, McGill University, Montreal, Canada.
Department of Family and Community Medicine and MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Infect Dis (Lond). 2024 Jan;56(1):66-72. doi: 10.1080/23744235.2023.2277390. Epub 2023 Dec 18.
Human papillomavirus (HPV) infection contributes to approximately 5% of the worldwide cancer burden. The three-dose HPV vaccine has demonstrated immunogenicity and efficacy. Humoral responses may be critical for preventing, controlling, and/or eliminating HPV infection. Using data from the HITCH cohort, we analysed humoral immune response to HPV vaccination among women in relation to the phylogenetic relatedness of HPV genotypes.
We included 96 women aged 18-24 years attending college or university in Montreal, Canada. Participants provided blood samples at enrolment and five follow-up visits. Antibody response to bacterially expressed L1 and E6 glutathione S-transferase fusion proteins of multiple Alphapapillomavirus types, and to virus-like particles (VLP-L1) of HPV16 and HPV18 were measured using multiplex serology. We assessed correlations between antibody seroreactivities using Pearson correlations (r).
At enrolment, 87.7% of participants were unvaccinated, 2.4% had received one, 3.2% two, and 6.7% three doses of HPV vaccine. The corresponding L1 seropositivity to any HPV was 41.2%, 83.3%, 100%, and 97.0%. Between-type correlations for L1 seroreactivities increased with the number of vaccine doses, from one to three. Among the latter, the strongest correlations were observed for HPV58-HPV33 (Pearson correlation [r] = 0.96; α9-species); HPV11-HPV6 ( = 0.96; α10-species); HPV45-HPV18 ( = 0.95; α7-species), and HPV68-HPV59 ( = 0.95; α7-species).
Correlations between HPV-specific antibody seroreactivities are affected by phylogenetic relatedness, with anti-L1 correlations becoming stronger with the number of vaccine doses received.
人乳头瘤病毒（HPV）感染约占全球癌症负担的 5%。三剂 HPV 疫苗已显示出免疫原性和疗效。体液免疫反应可能对预防、控制和/或消除 HPV 感染至关重要。利用 HITCH 队列的数据，我们分析了 HPV 疫苗接种后 HPV 基因型的系统发育相关性与女性 HPV 疫苗接种的体液免疫反应之间的关系。
我们纳入了 96 名年龄在 18-24 岁之间的在加拿大蒙特利尔上大学或学院的女性。参与者在入组时和五次随访时提供了血液样本。使用多重血清学方法测量了对细菌表达的 L1 和 E6 谷胱甘肽 S-转移酶融合蛋白以及 HPV16 和 HPV18 病毒样颗粒（VLP-L1）的多型 HPV 的抗体反应。我们使用 Pearson 相关性（r）评估了抗体反应的相关性。
在入组时，87.7%的参与者未接种疫苗，2.4%接种了一剂，3.2%接种了两剂，6.7%接种了三剂 HPV 疫苗。对任何 HPV 的 L1 血清阳性率分别为 41.2%、83.3%、100%和 97.0%。随着疫苗接种剂量的增加，L1 血清反应之间的类型相关性也随之增加，从一剂到三剂。在后者中，观察到最强的相关性是 HPV58-HPV33（Pearson 相关性 [r] = 0.96；α9 种）；HPV11-HPV6（r = 0.96；α10 种）；HPV45-HPV18（r = 0.95；α7 种）和 HPV68-HPV59（r = 0.95；α7 种）。
HPV 特异性抗体血清反应之间的相关性受系统发育关系的影响，随着接受疫苗剂量的增加，抗 L1 相关性增强。
